Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT04205357 Completed - Glioblastoma Clinical Trials

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

SAS-GKRS
Start date: March 1, 2020
Phase: Phase 1
Study type: Interventional

This study evaluates the safety associated with the addition of sulfasalazine to stereotactic radiosurgery for recurrent glioblastoma. Sulfasalazine is a potential tumor selective radiosensitizer.

NCT ID: NCT04186884 Completed - Clinical trials for Advanced Malignant Neoplasm

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

Start date: March 26, 2019
Phase:
Study type: Observational

This trial studies caregiver burden, quality of life, and symptom distress of patients and their informal (unpaid) caregivers at different palliative care settings. Cancer caregiving may affect a caregiver's life physically, emotionally, socially, and financially. Studying caregiver burden may help investigators learn about caregivers' opinions on stress of caregiving, and about the factors related to caregiver burdens.

NCT ID: NCT04186845 Completed - Prostate Cancer Clinical Trials

Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Start date: May 5, 2020
Phase: Phase 3
Study type: Interventional

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.

NCT ID: NCT04182178 Completed - Dysphagia Clinical Trials

Long-term Follow-up After Surgical Treatment for GERD (Gastroesophageal Reflux Disease)

Start date: August 5, 2019
Phase:
Study type: Observational

10 years of follow-up with SF-36 global (Quality of Life issues), GSRS (Gastrointestinal Symptom Rating Scale) and two reflux specific questionnaires.

NCT ID: NCT04181567 Completed - Clinical trials for Major Depressive Disorder

Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients

Start date: March 3, 2014
Phase: Phase 4
Study type: Interventional

Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants. The purpose of this study is to compare the efficacy, safety, and time to relapse/recurrence of ECT to ECT plus agomelatine in the treatment of patients with major depressive disorder. Inpatients with major depressive disorder for ECT will be randomly assigned to double-blind treatment with placebo or agomelatine 50 mg/d.

NCT ID: NCT04161040 Completed - Exercise Clinical Trials

Laboratory Model for Relapse to Sedentary Behavior

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

Physical inactivity is a key risk factor for noncommunicable illnesses such as cancer and cardiovascular disease-the two leading causes of death in West Virginia. The World Health Organization recommends muscle-strengthening activities 2 or more days per week and a minimum of either 150 minutes of moderate-intensity activity or 75 minutes of vigorous-intensity activity per week. Yet, only one in five adults in the United States meets these recommendations. Even more alarming is that 33.2% of West Virginians report that they did not engage in any physical activity in the past month. Incentive-based interventions increase physical activity in the short term, but incentives for healthy behavior are generally discontinued after some period of time, and relapse of unhealthy behavior is common. Thus, there is a critical need to develop interventions that result in both immediate and lasting engagement in activity. The overall objective and specific aim of the proposed project is to evaluate a brief laboratory model of relapse into sedentary behavior following incentive-based interventions that is based on Behavioral Momentum Theory. The central hypothesis is that incentives will increase activity, but relapse will occur in the brief model, like what occurs in extended clinical treatment. Development of a laboratory model of relapse into sedentary behavior (the expected outcome of the proposed project) will inform future translational research, eventually leading to clinical applications of large-scale physical-activity interventions that result in significant and immediate behavior change and that minimize relapse.

NCT ID: NCT04141618 Completed - Infertility Clinical Trials

The Role of NLRP Gene Family (NLRP1~14) in Recurrent Miscarriage and Infertility

Start date: August 2011
Phase:
Study type: Observational

Development of mole was not associated with segregation of mutated NLRP7 allele in the haploid oocyte. We hypothesize NLRP7 is a maternal factor involved in regulating early embryo development or embryo-uterine interaction. In the proposed study, we seek to identify novel genetic variants and mutations of NLRP7 in women who experienced RM/HM. Genetic association study and haplotype analysis are performed to test assocation between NLRP7 gene and female reproductive performance. Immunohistochemical staining, RT-PCR, and Western blot analysis are used to investigate expression pattern of NLRP7 in endometrium and placenta. Two approaches are used to characterize functional significance of genetic variants/mutations. The first approach will be based on mutagenesis and the second approach will be based on induced pluripotent stem cells (iPSCs). Results obtained from the proposed study will provide novel insight into mechanism of embryo development and implantation.

NCT ID: NCT04137575 Completed - Clinical trials for Breast Cancer Female

ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence

Start date: October 21, 2019
Phase: N/A
Study type: Interventional

The primary aim of this randomized controlled trial is to evaluate the effect of ConquerFear-Group (CF-G), compared with a control condition (CC), on Fear of Cancer Recurrence (FCR). Secondary aims are to explore the effect of CF-G on emotion regulation and additional psychological outcomes, and to explore mediating effects of emotion regulation, metacognitions, working alliance, patient adherence, and group cohesion. In addition, treatment expectancy, participation in other treatments after completion of the intervention of the study and demographic and clinical variables will be explored as moderators.

NCT ID: NCT04135963 Completed - Clinical trials for Relapse and/or Refractory Multiple Myeloma

A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

Start date: July 31, 2020
Phase:
Study type: Observational

The main aim of this study is to see how people with MM respond to previous or current treatment. Participants will be treated according to their clinic's standard practice. Each participant will fill out a study questionnaire during a routine doctor visit. Information collected from past medical records will also be used.

NCT ID: NCT04114877 Completed - Clinical trials for Postpartum Smoking Relapse

Perinatal Attentional Retraining Intervention for Smoking for Minority Women

PARIS
Start date: November 18, 2020
Phase: N/A
Study type: Interventional

The proposed research intends to randomize 50 abstinent pregnant Black or Hispanic smokers to receive either the attentional retraining (AR) or control VP task. Participants will be asked to carry around a smartphone as they go about their daily lives for 2 weeks in their last month of pregnancy (Phase 1). The smartphone will sound an alert randomly during the day, at which time participants will be asked to respond to a short set of questions assessing subjective states; this will be followed by a request to complete the AR (or control) procedures. This same procedure will be repeated for 2 weeks immediately after delivery (Phase 2). Women will undergo a follow-up visit 3 months after the end of Phase 2, and complete an unmodified VP and follow-up assessments.